336 related articles for article (PubMed ID: 32664510)
1. Galectin-3 Stimulates Tyro3 Receptor Tyrosine Kinase and Erk Signalling, Cell Survival and Migration in Human Cancer Cells.
Al Kafri N; Hafizi S
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32664510
[TBL] [Abstract][Full Text] [Related]
2. Tumour-Secreted Protein S (ProS1) Activates a Tyro3-Erk Signalling Axis and Protects Cancer Cells from Apoptosis.
Al Kafri N; Hafizi S
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31766614
[TBL] [Abstract][Full Text] [Related]
3. Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation.
Tsou WI; Nguyen KQ; Calarese DA; Garforth SJ; Antes AL; Smirnov SV; Almo SC; Birge RB; Kotenko SV
J Biol Chem; 2014 Sep; 289(37):25750-63. PubMed ID: 25074926
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells.
Vouri M; An Q; Birt M; Pilkington GJ; Hafizi S
Oncotarget; 2015 Jun; 6(18):16183-97. PubMed ID: 25980499
[TBL] [Abstract][Full Text] [Related]
5. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.
Lew ED; Oh J; Burrola PG; Lax I; Zagórska A; Través PG; Schlessinger J; Lemke G
Elife; 2014 Sep; 3():. PubMed ID: 25265470
[TBL] [Abstract][Full Text] [Related]
6. Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma.
Dantas-Barbosa C; Lesluyes T; Loarer FL; Chibon F; Treilleux I; Coindre JM; Meeus P; Brahmi M; Bally O; Ray-Coquard I; Sunyach MP; Cesne AL; Mir O; Bonvalot S; Toulmonde M; Italiano A; Saintigny P; Jean-Denis M; Ducimetiere F; Ranchere D; El Sayadi H; Alberti L; Blay JY
Br J Cancer; 2017 Dec; 117(12):1787-1797. PubMed ID: 29024938
[TBL] [Abstract][Full Text] [Related]
7. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
[TBL] [Abstract][Full Text] [Related]
8. Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL.
Abboud-Jarrous G; Priya S; Maimon A; Fischman S; Cohen-Elisha M; Czerninski R; Burstyn-Cohen T
Oncotarget; 2017 Feb; 8(8):13986-14002. PubMed ID: 28118606
[TBL] [Abstract][Full Text] [Related]
9. Expression of the vitamin K-dependent proteins GAS6 and protein S and the TAM receptor tyrosine kinases in human atherosclerotic carotid plaques.
Hurtado B; Muñoz X; Recarte-Pelz P; García N; Luque A; Krupinski J; Sala N; García de Frutos P
Thromb Haemost; 2011 May; 105(5):873-82. PubMed ID: 21384080
[TBL] [Abstract][Full Text] [Related]
10. Cross-phosphorylation, signaling and proliferative functions of the Tyro3 and Axl receptors in Rat2 cells.
Brown JE; Krodel M; Pazos M; Lai C; Prieto AL
PLoS One; 2012; 7(5):e36800. PubMed ID: 22606290
[TBL] [Abstract][Full Text] [Related]
11. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
[TBL] [Abstract][Full Text] [Related]
12. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
[TBL] [Abstract][Full Text] [Related]
13. Anticancer effect of luteolin is mediated by downregulation of TAM receptor tyrosine kinases, but not interleukin-8, in non-small cell lung cancer cells.
Lee YJ; Lim T; Han MS; Lee SH; Baek SH; Nan HY; Lee C
Oncol Rep; 2017 Feb; 37(2):1219-1226. PubMed ID: 28035396
[TBL] [Abstract][Full Text] [Related]
14. Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation.
Zhou J; Yang A; Wang Y; Chen F; Zhao Z; Davra V; Suzuki-Inoue K; Ozaki Y; Birge RB; Lu Q; Wu Y
Cell Commun Signal; 2018 Dec; 16(1):98. PubMed ID: 30541554
[TBL] [Abstract][Full Text] [Related]
15. The first laminin G-like domain of protein S is essential for binding and activation of Tyro3 receptor and intracellular signalling.
Al Kafri N; Ahnström J; Teraz-Orosz A; Chaput L; Singh N; Villoutreix BO; Hafizi S
Biochem Biophys Rep; 2022 Jul; 30():101263. PubMed ID: 35518197
[TBL] [Abstract][Full Text] [Related]
16. The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.
Antony J; Zanini E; Kelly Z; Tan TZ; Karali E; Alomary M; Jung Y; Nixon K; Cunnea P; Fotopoulou C; Paterson A; Roy-Nawathe S; Mills GB; Huang RY; Thiery JP; Gabra H; Recchi C
EMBO Rep; 2018 Aug; 19(8):. PubMed ID: 29907679
[TBL] [Abstract][Full Text] [Related]
17. The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer.
Uribe DJ; Mandell EK; Watson A; Martinez JD; Leighton JA; Ghosh S; Rothlin CV
PLoS One; 2017; 12(7):e0179979. PubMed ID: 28727830
[TBL] [Abstract][Full Text] [Related]
18. The TAM Subfamily of Receptor Tyrosine Kinases: The Early Years.
Prieto AL; Lai C
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542343
[TBL] [Abstract][Full Text] [Related]
19. The role of TAM family receptors and ligands in the nervous system: From development to pathobiology.
Shafit-Zagardo B; Gruber RC; DuBois JC
Pharmacol Ther; 2018 Aug; 188():97-117. PubMed ID: 29514053
[TBL] [Abstract][Full Text] [Related]
20. Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.
Sadahiro H; Kang KD; Gibson JT; Minata M; Yu H; Shi J; Chhipa R; Chen Z; Lu S; Simoni Y; Furuta T; Sabit H; Zhang S; Bastola S; Yamaguchi S; Alsheikh H; Komarova S; Wang J; Kim SH; Hambardzumyan D; Lu X; Newell EW; DasGupta B; Nakada M; Lee LJ; Nabors B; Norian LA; Nakano I
Cancer Res; 2018 Jun; 78(11):3002-3013. PubMed ID: 29531161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
